---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-015895"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:46:06.935060+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma posts first revenue of $3.9M from LYMPHIR launch; Nasdaq warns of bid price deficiency

## Summary
- Q1 FY2026 revenue $3.9M from initial LYMPHIR sales; net loss $8.2M ($0.41 loss per share).
- Cash and equivalents $7.7M; raised ~$20.9M from equity financings in quarter.
- Nasdaq notified company of bid price deficiency; has until Aug 10, 2026 to regain compliance.
- LYMPHIR launched Dec 2025; early physician adoption; international patient access via Named Patient Programs.
- Late-stage pipeline includes Mino-Lok and Halo-Lido; engaging with FDA on next steps.

## SEC filing metadata
- accession: 0001213900-26-015895
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/0001213900-26-015895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/ea0276948-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-015895
- JSON: https://secwatch.observer/filing/0001213900-26-015895.json
- Plain text: https://secwatch.observer/filing/0001213900-26-015895.txt

## Source-grounded claims
- claim_id: b1fb80ef4bb1d9b150520e22077335e2a585d4f4
  claim: Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  evidence_excerpt: February 9, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until August 10, 2026, to regain compliance with the Bid Price Rule. If at any time before August 10, 2026, the bid price of the Company's co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/0001213900-26-015895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.